nach oben

Erschienen in:

18.04.2018 | Original Article

Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival

verfasst von: Joo Young Kim, Sang Hwa Lee, Soyeon An, Sung Joo Kim, You-Na Sung, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Seung-Mo Hong

Erschienen in: Virchows Archiv | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Well-differentiated pancreatic neuroendocrine neoplasms/tumors (PanNETs) are rare neoplasms with diverse clinical behavior. Biomarker discovery is important for predicting clinical course and prognosis of PanNET patients. Carbonic anhydrase 9 (CA9) and vimentin are hypoxia and epithelial-mesenchymal transition-related proteins of which expression in many carcinomas has been associated with poor prognosis, but their significance in PanNET has yet to be determined. We assessed CA9 and vimentin expression in 164 PanNETs and compared this with clinicopathologic characteristics. CA9 expression was observed in normal islets, while neuroendocrine microadenomas and small (< 1 cm) PanNETs showed loss of CA9 expression. CA9 and vimentin expression was observed in 38 (23%) and 36 (22%) of PanNETs, respectively. CA9 expression was associated with larger size (p = 0.001), higher grade (p < 0.001), higher pT category (p < 0.001), lymph node (p = 0.003) and distant (p = 0.047) metastases, higher AJCC stage (p < 0.001), and lymphovascular (p < 0.001) and perineural (p = 0.002) invasion. PanNET patients with CA9 expression had a shorter recurrence-free survival (5-year survival rate 47%) than those without CA9 expression (76%) by univariate (p = 0.001) but not multivariate analysis. Vimentin expression correlated with CA9 expression (p < 0.001) but not with other clinicopathologic factors. In conclusion, CA9 expression was observed in normal islets, while neuroendocrine microadenomas and small (< 1 cm) PanNETs showed CA9 expression loss. CA9 expression gradually reappeared in larger PanNETs, and this was associated with clinical progression and decreased patient survival by univariate but not multivariate analysis.

Nur mit Berechtigung zugänglich

Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds) (2017) WHO classification of tumours of endocrine organs, 4th edn. International Agency for Research on Cancer, Lyon

Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Büchler MW (2008) Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 95(5):627–635. https://doi.org/10.1002/bjs.6051 CrossRefPubMed

Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ (2008) Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 247(3):490–500. https://doi.org/10.1097/SLA.0b013e31815b9cae CrossRefPubMed

Fesinmeyer MD, Austin MA, Li CI et al (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomark Prev 14(7):1766–1773. https://doi.org/10.1158/1055-9965.EPI-05-0120 CrossRef

Halfdanarson TR, Rabe KG, Rubin J, Petersen GM (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19(10):1727–1733. https://doi.org/10.1093/annonc/mdn351 CrossRefPubMedPubMedCentral

Kulke MH, Shah MH, Benson AB 3rd et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw 13(1):78–108CrossRef

Amin S, Kim MK (2016) Islet cell tumors of the pancreas. Gastroenterol Clin N Am 45(1):83–100. https://doi.org/10.1016/j.gtc.2015.10.007 CrossRef

Edge SB, Byrd DR, Compton CC et al (2010) AJCC Cancer Staging Manual. Springer New York. In: NY

Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401. https://doi.org/10.1007/s00428-006-0250-1 CrossRefPubMedPubMedCentral

10.

Liu TC, Hamilton N, Hawkins W, Gao F, Cao D (2013) Comparison of WHO classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 37(6):853–859. https://doi.org/10.1097/PAS.0b013e31827fcc18 CrossRefPubMedPubMedCentral

11.

Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK (2011) Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 29(22):3044–3049. https://doi.org/10.1200/JCO.2011.35.1817 CrossRefPubMed

12.

Wang L, Yang M, Zhang Y et al (2015) Prognostic validation of the WHO 2010 grading system in pancreatic insulinoma patients. Neoplasma 62(3):484–490. https://doi.org/10.4149/neo_2015_058 CrossRefPubMed

13.

Son EM, Kim JY, An S, Song KB, Kim SC, Yu E, Hong SM (2015) Clinical and prognostic significances of cytokeratin 19 and KIT expression in surgically resectable pancreatic neuroendocrine tumors. J Pathol Transl Med 49(1):30–36. https://doi.org/10.4132/jptm.2014.10.23 CrossRefPubMedPubMedCentral

14.

Sakai Y, Hong SM, An S, Kim JY, Corbeil D, Karbanová J, Otani K, Fujikura K, Song KB, Kim SC, Akita M, Nanno Y, Toyama H, Fukumoto T, Ku Y, Hirose T, Itoh T, Zen Y (2017) CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses. Hum Pathol 61:148–157. https://doi.org/10.1016/j.humpath.2016.10.022 CrossRefPubMed

15.

Deshpande V, Fernandez-del Castillo C, Muzikansky A, Deshpande A, Zukerberg L, Warshaw AL, Lauwers GY (2004) Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 28(9):1145–1153CrossRefPubMed

16.

Ali A, Serra S, Asa SL, Chetty R (2006) The predictive value of CK19 and CD99 in pancreatic endocrine tumors. Am J Surg Pathol 30(12):1588–1594. https://doi.org/10.1097/01.pas.0000213309.51553.01 CrossRefPubMed

17.

Zhang L, Smyrk TC, Oliveira AM, Lohse CM, Zhang S, Johnson MR, Lloyd RV (2009) KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol 33(10):1562–1569. https://doi.org/10.1097/PAS.0b013e3181ac675b CrossRefPubMed

18.

Han X, Zhao J, Ji Y, Xu X, Lou W (2013) Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors. Tumour Biol 34(5):2881–2889. https://doi.org/10.1007/s13277-013-0850-8 CrossRefPubMed

19.

La Rosa S, Rigoli E, Uccella S et al (2007) Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. Histopathology 50(5):597–606. https://doi.org/10.1111/j.1365-2559.2007.02662.x CrossRefPubMed

20.

Kim JY, Kim MS, Kim KS, Song KB, Lee SH, Hwang DW, Kim KP, Kim HJ, Yu E, Kim SC, Jang HJ, Hong SM (2015) Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors. Am J Surg Pathol 39(5):592–601. https://doi.org/10.1097/PAS.0000000000000383 CrossRefPubMed

21.

Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021):1199–1203. https://doi.org/10.1126/science.1200609 CrossRefPubMedPubMedCentral

22.

Krausch M, Raffel A, Anlauf M, Schott M, Willenberg H, Lehwald N, Hafner D, Cupisti K, Eisenberger C, Knoefel W (2011) Loss of PTEN expression in neuroendocrine pancreatic tumors. Horm Metab Res 43(12):865–871. https://doi.org/10.1055/s-0031-1291333 CrossRefPubMed

23.

Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel E–J, Perren A (2014) Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146(2):453–460 e455. https://doi.org/10.1053/j.gastro.2013.10.020 CrossRefPubMed

24.

Scarpa A, Chang DK, Nones K et al (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543(7643):65–71. https://doi.org/10.1038/nature21063 CrossRefPubMed

25.

Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SKN, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333(6041):425. https://doi.org/10.1126/science.1207313 CrossRefPubMedPubMedCentral

26.

Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM (2017) Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clin Cancer Res 23(6):1598–1606. https://doi.org/10.1158/1078-0432.CCR-16-1147 CrossRefPubMed

27.

Dogeas E, Karagkounis G, Heaphy CM, Hirose K, Pawlik TM, Wolfgang CL, Meeker A, Hruban RH, Cameron JL, Choti MA (2014) Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases. J Am Coll Surg 218(4):628–635. https://doi.org/10.1016/j.jamcollsurg.2014.01.001 CrossRefPubMedPubMedCentral

28.

Svastova E, Zilka N, Zat'ovicova M et al (2003) Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 290(2):332–345CrossRefPubMed

29.

Shin HJ, Rho SB, Jung DC, Han IO, Oh ES, Kim JY (2011) Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. J Cell Sci 124(Pt 7):1077–1087. https://doi.org/10.1242/jcs.072207 CrossRefPubMed

30.

Zeisberg M, Neilson EG (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119(6):1429–1437. https://doi.org/10.1172/JCI36183 CrossRefPubMedPubMedCentral

31.

Bernstein JM, Andrews TD, Slevin NJ, West CML, Homer JJ (2015) Prognostic value of hypoxia-associated markers in advanced larynx and hypopharynx squamous cell carcinoma. Laryngoscope 125(1):E8–E15. https://doi.org/10.1002/lary.24933

32.

Kang HJ, Kim IH, Sung CO, Shim JH, Yu E (2015) Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma. Virchows Arch 466(4):403–413. https://doi.org/10.1007/s00428-014-1709-0 CrossRefPubMed

33.

Dauphin M, Barbe C, Lemaire S, Nawrocki-Raby B, Lagonotte E, Delepine G, Birembaut P, Gilles C, Polette M (2013) Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer 81(1):117–122. https://doi.org/10.1016/j.lungcan.2013.03.011 CrossRefPubMed

34.

Otsuki S, Inokuchi M, Enjoji M et al (2011) Vimentin expression is associated with decreased survival in gastric cancer. Oncol Rep 25(5):1235–1242. https://doi.org/10.3892/or.2011.1185 PubMedCrossRef

35.

Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-Vuorinen A, Soini Y (2013) Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res Treat 138(1):81–90. https://doi.org/10.1007/s10549-013-2442-0 CrossRefPubMed

36.

Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, DeMarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA (2012) Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36(2):173–184. https://doi.org/10.1097/PAS.0b013e3182417d36 CrossRefPubMedPubMedCentral

37.

Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS (2015) The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 39(5):683–690. https://doi.org/10.1097/PAS.0000000000000408 CrossRefPubMedPubMedCentral

38.

Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS (2012) Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 36(12):1761–1770. https://doi.org/10.1097/PAS.0b013e318263207c CrossRefPubMed

39.

Kim SJ, An S, Lee JH, Kim JY, Song KB, Hwang DW, Kim SC, Yu E, Hong SM (2017) Loss of progesterone receptor expression is an early tumorigenesis event associated with tumor progression and shorter survival in pancreatic neuroendocrine tumor patients. J Pathol Transl Med 51:388–395. https://doi.org/10.4132/jptm.2017.03.19 CrossRefPubMedPubMedCentral

40.

Jarvela S, Parkkila S, Bragge H et al (2008) Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 8:1. https://doi.org/10.1186/1471-2407-8-1 CrossRefPubMedPubMedCentral

41.

Lin J, Lu J, Wang C et al (2017) The prognostic values of the expression of vimentin, TP53, and podoplanin in patients with cervical cancer. Cancer Cell Int 17:80. https://doi.org/10.1186/s12935-017-0450-6 CrossRefPubMedPubMedCentral

42.

Harris AL (2002) Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47. https://doi.org/10.1038/nrc704 CrossRefPubMed

43.

McDonald PC, Winum JY, Supuran CT et al (2012) Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3(1):84–97. https://doi.org/10.18632/oncotarget.422 CrossRefPubMedPubMedCentral

44.

Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92(1):94–101. https://doi.org/10.1038/sj.bjc.6602245 CrossRefPubMed

45.

Deschamps L, Bacha D, Rebours V, Mebarki M, Bretagnol F, Panis Y, Bedossa P, Ruszniewski P, Couvelard A (2012) The expression of the hypoxia markers CA9 and CXCR4 is correlated with survival in patients with neuroendocrine tumours of the ileum. Neuroendocrinology 95(3):214–222. https://doi.org/10.1159/000329873 CrossRefPubMed

46.

O'Toole D, Couvelard A, Rebours V, Zappa M, Hentic O, Hammel P, Levy P, Bedossa P, Raymond E, Ruszniewski P (2010) Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer 17(4):847–856. https://doi.org/10.1677/ERC-09-0204 CrossRefPubMed

47.

Speisky D, Duces A, Bieche I, Rebours V, Hammel P, Sauvanet A, Richard S, Bedossa P, Vidaud M, Murat A, Niccoli P, Scoazec JY, Ruszniewski P, Couvelard A, for the GTE Group (Groupe d'Etude des Tumeurs Endocrines) (2012) Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. Clin Cancer Res 18(10):2838–2849. https://doi.org/10.1158/1078-0432.CCR-11-2759 CrossRefPubMed

48.

Chen J, Rocken C, Hoffmann J et al (2005) Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 54(7):920–927. https://doi.org/10.1136/gut.2004.047340 CrossRefPubMedPubMedCentral

49.

Kockar F, Yildrim H, Sagkan RI, Hagemann C, Soysal Y, Anacker J, Hamza AA, Vordermark D, Flentje M, Said HM (2012) Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro. World J Clin Oncol 3(6):82–91. https://doi.org/10.5306/wjco.v3.i6.82 CrossRefPubMedPubMedCentral

50.

Galvan JA, Astudillo A, Vallina A, Fonseca PJ, Gomez-Izquierdo L, Garcia-Carbonero R, Gonzalez MV (2013) Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol 140(1):61–72. https://doi.org/10.1309/AJCPIV40ISTBXRAX CrossRefPubMed

51.

Watanabe A, Cornelison R, Hostetter G (2005) Tissue microarrays: applications in genomic research. Expert Rev Mol Diagn 5(2):171–181. https://doi.org/10.1586/14737159.5.2.171 CrossRefPubMed

Titel: Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival
verfasst von: Joo Young Kim
Sang Hwa Lee
Soyeon An
Sung Joo Kim
You-Na Sung
Ki-Byung Song
Dae Wook Hwang
Song Cheol Kim
Seung-Mo Hong
Publikationsdatum: 18.04.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 5/2018
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2353-x

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Lymphomas in IgG4-related disease: clinicopathologic features in a Western population

The landscape of genetic alterations in ameloblastomas relates to clinical features

Breast sebaceous carcinoma—a rare entity. Clinico-pathological description of two cases and brief review

FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer

Metastatic non-small cell lung carcinoma a mimic of primary breast carcinoma—case series and literature review

Monoclonal gammopathy of renal significance presenting as monotypic plasma cell interstitial nephritis in two patients with Sjögren’s syndrome

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien